Abstract

The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals:



Formula I

wherein n is an integer, preferably n is 1;

wherein R_1 and R_2 are independently selected from the group consisting of:



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number
WO 2004/011456 A1

(51) International Patent Classification[7]: C07D 401/14, A61K 31/506, A61P 35/00

(21) International Application Number: PCT/CA2003/001162

(22) International Filing Date: 31 July 2003 (31.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/399,408 31 July 2002 (31.07.2002) US

(71) Applicant and
(72) Inventor: DANTER, Wayne, R., [CA/CA]; 147 Chesham Avenue, London, Ontario N6G 3V2 (CA).

(71) Applicants and
(72) Inventors (*for US only*): BROWN, Martyn [GB/CA]; 349 Wildcat Road, Toronto, Ontario M3J 2S3, Canada (CA). MA, George [GB/CA]; 349 Wildcat Road, Toronto, Ontario M3J 2S3 (CA).

(71) Applicants and
(72) Inventors (*for US only*): RUSU, Ghenadie [MD/CA]; 349 Wildcat Road, Toronto, Ontario M3J 2S3 (CA). ZHONG, Jianhua [CA/CA]; 349 Wildcat Road, Toronto, Ontario M3J 2S3,, Canada (CA). LAZAROWYCH, Natalie [CA/CA]; 349 Wildcat Road, Toronto, Ontario M3J 2S3 (CA). HOULDSWORTH, Stephen [GB/CA]; 349 Wildcat Road, Toronto, Ontario M3J 2S3 (CA).

(74) Agent: MCMANUS, Kimberly, A.,; Sim & McBurney, 330 University Avenue, Sixth Floor, Toronto, Ontario M5G 1R7 (CA).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROTEIN TYROSINE KINASE INHIBITORS



(I)

(57) Abstract: The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals:wherein n is an integer, preferably n is 1;wherein R_1 and R_2 are independently selected from the group consisting of:wherein R3 is selected from the group consisting of H; alkyl; alkenyl; alkynyl; halogen; aryl; heteroaryl containing N, O, or S; the aryl and heteroaryl may be further substituted with halogen, an alkyl, alkenyl, and alkynyl; NZ_1Z_2, wherein Z_1 and Z_2 are independently selected from the group consisting of H and alkyl; and (CO)Y wherein Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl containing N, O, or S, and the aryl and heteroaryl may be further substituted with halogen, alkyl, alkenyl, and alkynyl; andwherein R_4 is selected from the group consisting of H and alkyl.

WO 2004/011456 A1